All Penny Stocks.com News: Elite Pharmaceuticals Sees Strong Revenue Growth in Q3

Mississauga, ON -- (SBWIRE) -- 02/10/2016 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Elite Pharmaceuticals Sees Strong Revenue Growth in Q3."

Companies mentioned in this article include iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB), Gilead Sciences Inc. (NASDAQ:GILD), Amgen Inc. (NASDAQ:AMGN), Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Elite Pharmaceuticals Inc. (OTCQB:ELTP).

Article Excerpt:

After three successive days of losses, U.S. equities have rebounded sharply in trading today led by the NASDAQ. The NASDAQ is gaining on the back of a sharp rebound in the technology and biotechnology sectors. Both sectors have been hammered lately.

The biotechnology sector, in particular, has come under significant selling pressure during the current sell-off. Before today's bounce back, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) had fallen more than 26%. The IBB is up more than 3% in mid-day trading.

The sharp pullback in biotech stocks though has led to some attractive valuations. Gilead Sciences Inc. (NASDAQ:GILD), which recently reported strong fourth-quarter results and also guided for more than $30 billion in 2016 revenue, is now trading at just 7.5x earnings. This is significantly below the average for the S&P 500. Another large cap biotechnology company that is trading at low multiples is Amgen Inc. (NASDAQ:AMGN). Although not as cheap as Gilead, Amgen is still trading at a discount to the S&P 500. AMGN currently trades at P/E ratio of 16.20x. AMGN also has a dividend yield of 2.72%.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/612/elite-pharmaceuticals-sees-strong-revenue-growth-in-q3.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:

AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.

For more information on this press release visit: http://www.sbwire.com/press-releases/all-penny-stockscom-news-elite-pharmaceuticals-sees-strong-revenue-growth-in-q3-664246.htm